Bristol Myers Squibb’s drug Sotyktu, originally approved for plaque psoriasis, has shown positive results in two pivotal tests for psoriatic arthritis. Expanding approval to include this condition could increase revenue for the drug. Sotykut targets the enzyme TYK2, offering patients an alternative treatment option with potentially better safety than other Janus kinase (JAK) inhibitors. The drug met primary goals in Phase 3 trials for psoriatic arthritis and demonstrated a good safety profile. BMS is competing with other companies developing similar drugs and hopes to maintain its market position. Sotykut has shown revenue growth and is also being studied for other autoimmune conditions.
Source link
Bristol Myers Squibb’s Sotyktu Meets Goals in Two Pivotal Psoriatic Arthritis Studies
